Skip to main content
main-content

Oncology

Editor's pick

Broad-based genomic screening benefits questioned for advanced NSCLC

DNA sequencing concept illustration

Most patients being treated in the community setting for advanced nonsquamous non-small-cell lung cancer do not benefit from the use of broad-based genomic sequencing, suggests a study comparing this approach with routine testing for only epidermal growth factor receptor and anaplastic lymphoma kinase alterations.

ASCO 2018: Abi Race trial in prostate cancer

Lead author Daniel George discusses his team's findings of a greater and longer lasting treatment effect with abiraterone acetate and prednisone in Black than White men with metastatic castration-resistance prostate cancer (3:59). 

ASCO 2018: CARMENA trial in renal cell carcinoma

Arnaud Méjean presents the CARMENA trial findings, suggesting that cytoreductive nephrectomy may no longer be the standard of care for metastatic renal cell carcinoma in the era of sunitinib (4:21).

ASCO 2018: TAILORx trial in breast cancer

Joseph Sparano gives an overview of his team's findings regarding a 21-gene prognostic test that could help tailor treatment for women with early breast cancer (3:24).

ASCO 2018: IMPACT trial across multiple cancers

Apostolia Tsimberidou discusses the findings of the IMPACT study, looking at the survival benefits of matching targeted treatments to the genetic alterations of tumors across multiple cancer types (7:56).

15-08-2018 | Oncology | News | Article

Apatinib–etoposide shows promise in platinum-resistant ovarian cancer

Oral etoposide plus apatinib is associated with a good objective response rate and manageable toxicity in heavily pretreated Chinese women with platinum-resistant or refractory ovarian cancer, according to results of the phase II AEROC study.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30349-8
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30444-3

14-08-2018 | Oncology | News | Article

Preoperative antivirals lower recurrence risk in HBV-related liver cancer

Patients who receive antiviral therapy for more than 90 days prior to hepatectomy for hepatitis B virus-related hepatocellular carcinoma have a reduced risk for microvascular invasion and early tumor recurrence, Chinese research shows.

Source:

JAMA Surg 2018; doi:10.1001/jamasurg.2018.2721
JAMA Surg 2018; doi:10.1001/jamasurg.2018.2728

13-08-2018 | Oncology | News | Article

Ibrutinib monotherapy promising for untreated Waldenström macroglobulinemia

Phase II trial results suggest that the Bruton tyrosine kinase inhibitor ibrutinib has high activity and is well tolerated in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.78.6426
J Clin Oncol 2018; doi:10.1200/JCO.2018.79.3273

13-08-2018 | Oncology | News | Article

approvalsWatch

Mogamulizumab-kpkc approved for rare NHL subtypes

Read more on this US FDA decision here

BRIM Trials Analysis Identifies BRAF-Mutated Metastatic Melanoma Survival Predictors

The outcome of patients using BRAF and/or MEK inhibitors for metastatic melanoma is significantly linked to four different clinical and tumour-related biomarkers Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

Twitter Icon Follow medwireNews

Click here
image credits